Between Our Cell Phones and Our Wearables, We Generate
More Data in the Day Than Doctors Used to See in a Year…
Connect to share insights with doctors, researchers, and regulators on WHAT MATTERS MOST to YOU. The A-LIST is an active cohort of individuals living with or at risk for Alzheimer’s/dementia/MCI diseases, including current and former care partners. With more than 5,000 members across diverse communities along the Alzheimer’s journey, we are doing our part to accelerate research toward a cure. HIPPA compliant: IRB pending.
14.9 Million Care for Someone Who Has Alzheimer’s Disease or Other Dementia.
BETA TEST!
Ginger.io – Listener App
Need someone to talk to? Are you a caregiver? Do you feel isolated? Is it awkward to discuss how hard it is to cope? Wouldn’t it be nice to talk to someone who gets it? That’s why we’ve built Listener. We believe that small conversations make a big impact on our long-term wellbeing. Connect with a highly trained listener through our simple smartphone app. We’re here for you 24/7. We respect your privacy. All conversations are confidential. Learn More…
Every 68 Seconds, Another Alzheimer’s Diagnosis.
DOWNLOAD!
The Conversation Project Starter Kit
“It’s always too soon, before it’s too late” Have you had the conversation?
The Conversation Project is dedicated to helping people talk about their wishes for end-of-life care. We believe that the place for this to begin is at the kitchen table—not in the intensive care unit or dementia ward —with the people we love, before it’s too late. Make sure that your own wishes and those of our loved ones are expressed and respected. Learn more…
Cognitive Vitality
Can you protect yourself against dementia? The Alzheimer’s Drug Discovery Foundation, a leader in AD drug and therapy development brings you www.CognitiveVitality.org. This new site rates the scientific evidence behind the safety and effectiveness of any treatment suggested to protect the aging brain, such as resveratrol, fish oil, coffee, hormone therapy, anti-hypertensive drugs, and more. Timely updates. Learn more…
Alzheimer’s & Other Dementias Daily Companion
Your On-the-Go Guide for Dementia Care Advice Alzheimer’s & Other Dementias Daily Companion is an app that caregivers can use when they need an idea with a specific situation. It’s broken out into topics such as hygiene, aggressive behavior, etc. Learn more…
Sexx matters. Women are 2X more at risk to develop AD, and account for nearly two-thirds of unpaid caregivers.
SIGN UP!
A4 Clinical Trial
The A4 Trial is a landmark clinical trial to prevent the memory loss associated with Alzheimer’s disease. Healthy adults, ages 65-85, with normal thinking and memory abilities are currently being recruited at research centers nationwide. The A4 study is designed to test whether a new investigational treatment can slow memory loss associated with Alzheimer’s disease. Don’t just be concerned about memory loss. Opt in for Research. Learn more…
Prevention Registry
The Geoffrey Beene Foundation Alzheimer’s Initiative helped provide catalyst funding for the Alzheimer’s Prevention Registry, developed in collaboration with the Banner Alzheimer’s Institute. It’s the first online, Alzheimer’s disease national Prevention Registry created specifically to recruit pre-symptomatic subjects for treatments or interventions that will postpone, slow or prevent the disease’s progress. The Registry provides people who want to see an end to this disease a simple and meaningful way to help. Learn more…
SNIFF — Study of Nasal Insulin to Fight Forgetfulness
There is growing evidence that poor regulation of insulin may make it difficult for the brain to function optimally and may contribute to the development of Alzheimer’s
The purpose of the SNIFF study is to find out whether a type of insulin, when administered as a nasal spray, improves memory in adults with a mild memory impairment or Alzheimer’s disease.. SNIFF will test a therapy aimed at using insulin to see if these deficiencies can be corrected. Learn more…
NCA&T
Alzheimer’s disease occurs more often in African Americans than in Caucasians. By studying many people with Alzheimer’s disease, researchers at North Carolina A&T State University and the John P. Hussman Institute for Human Genomics hope to find genes (inherited material) that may cause Alzheimer’s disease in African-Americans. The goals of this research study are to find the genetic causes of Alzheimer’s disease and to improve Alzheimer’s tests and treatments for African-Americans. Learn more…
MINDSET–Phase III clinical research program evaluating RVT-101 for mild-to-moderate Alzheimer’s disease
RVT-101 has already been tested in 13 clinical trials, including a 684-subject study where it was found to have statistically significant benefits on cognition and ability to perform daily tasks as compared to donepezil alone. If approved, this will be the first new Alzheimer’s drug on the market in 17 years. It is important to have African Americans participating in this trial to make sure it is both safe and effective for us. African Americans are at least twice as likely to develop Alzheimer’s as White Americans, yet we are significantly underrepresented in clinical research. Only 5 percent of research participants are African Americans despite being over 13 percent of the population. To ensure that treatments work for everyone, everyone must participate! Learn more…
Are you one of the 15 million caregivers looking after a loved one with Alzheimer’s or other dementia? Help scientists understand how caregiving impacts brain performance. Join the Caregivers’ Health-eBrain project and participate in an online study to assess your cognition.
Disclaimer
The content on E-Lab is intended solely for virtual research studies and beta testing. IT IS NOT INTENDED TO PROVIDE, AND DOES NOT PROVIDE, ANY MEDICAL ADVICE. IT DOES NOT RECOMMEND OR ENDORSE ANY SPECIFIC ACTIONS OR COURSE OF CONDUCT. We encourage you to consult with your own healthcare providers when making decisions regarding your health.